866 related articles for article (PubMed ID: 23666091)
1. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease.
Gaggini M; Morelli M; Buzzigoli E; DeFronzo RA; Bugianesi E; Gastaldelli A
Nutrients; 2013 May; 5(5):1544-60. PubMed ID: 23666091
[TBL] [Abstract][Full Text] [Related]
2. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps.
Santos RD; Valenti L; Romeo S
Atherosclerosis; 2019 Mar; 282():110-120. PubMed ID: 30731283
[TBL] [Abstract][Full Text] [Related]
3. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis.
Cusi K
Clin Liver Dis; 2009 Nov; 13(4):545-63. PubMed ID: 19818304
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
[TBL] [Abstract][Full Text] [Related]
5. Interrelationships between hepatic fat and insulin resistance in non-alcoholic fatty liver disease.
Lockman KA; Nyirenda MJ
Curr Diabetes Rev; 2010 Sep; 6(5):341-7. PubMed ID: 20701585
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Simon TG; Corey KE; Chung RT; Giugliano R
Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
[TBL] [Abstract][Full Text] [Related]
7. Role of transcription factor modifications in the pathogenesis of insulin resistance.
Kim MY; Bae JS; Kim TH; Park JM; Ahn YH
Exp Diabetes Res; 2012; 2012():716425. PubMed ID: 22110478
[TBL] [Abstract][Full Text] [Related]
8. Reproducibility of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with non-alcoholic fatty liver disease.
Magkos F; Fabbrini E; Korenblat K; Okunade AL; Patterson BW; Klein S
Int J Obes (Lond); 2011 Sep; 35(9):1233-40. PubMed ID: 21179000
[TBL] [Abstract][Full Text] [Related]
9. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
[TBL] [Abstract][Full Text] [Related]
10. Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people.
Sung KC; Wild SH; Kwag HJ; Byrne CD
Diabetes Care; 2012 Nov; 35(11):2359-64. PubMed ID: 22829522
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.
Bugianesi E; Gastaldelli A; Vanni E; Gambino R; Cassader M; Baldi S; Ponti V; Pagano G; Ferrannini E; Rizzetto M
Diabetologia; 2005 Apr; 48(4):634-42. PubMed ID: 15747110
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments.
Scorletti E; Calder PC; Byrne CD
Endocrine; 2011 Dec; 40(3):332-43. PubMed ID: 21894514
[TBL] [Abstract][Full Text] [Related]
15. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.
Lomonaco R; Ortiz-Lopez C; Orsak B; Webb A; Hardies J; Darland C; Finch J; Gastaldelli A; Harrison S; Tio F; Cusi K
Hepatology; 2012 May; 55(5):1389-97. PubMed ID: 22183689
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease.
Bhat G; Baba CS; Pandey A; Kumari N; Choudhuri G
Trop Gastroenterol; 2013; 34(1):18-24. PubMed ID: 23923370
[TBL] [Abstract][Full Text] [Related]
17. Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice.
Chiang H; Lee JC; Huang HC; Huang H; Liu HK; Huang C
Br J Pharmacol; 2020 Jan; 177(2):239-253. PubMed ID: 31497874
[TBL] [Abstract][Full Text] [Related]
18. Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with Type 2 diabetes.
Barchetta I; Angelico F; Del Ben M; Di Martino M; Cimini FA; Bertoccini L; Polimeni L; Catalano C; Fraioli A; Del Vescovo R; Morini S; Baroni MG; Cavallo MG
Clin Sci (Lond); 2016 Oct; 130(19):1753-62. PubMed ID: 27458255
[TBL] [Abstract][Full Text] [Related]
19. Fatty liver and insulin resistance in children with hypobetalipoproteinemia: the importance of aetiology.
Della Corte C; Fintini D; Giordano U; Cappa M; Brufani C; Majo F; Mennini C; Nobili V
Clin Endocrinol (Oxf); 2013 Jul; 79(1):49-54. PubMed ID: 22789032
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome and non-alcoholic fatty liver disease.
Almeda-Valdés P; Cuevas-Ramos D; Aguilar-Salinas CA
Ann Hepatol; 2009; 8 Suppl 1():S18-24. PubMed ID: 19381120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
